Year All2024202320222021202020192018201720162015 Poseida Therapeutics to Present at Two Upcoming Investor Conferences November 8, 2022 Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress November 3, 2022 Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition November 3, 2022 Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting October 5, 2022 Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference September 7, 2022 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 August 11, 2022 Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares August 8, 2022 Poseida Therapeutics Announces Pricing of Public Offering of Common Stock August 4, 2022 Poseida Therapeutics Announces Proposed Public Offering of Common Stock August 3, 2022 Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies August 3, 2022
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition November 3, 2022
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting October 5, 2022
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference September 7, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 August 11, 2022
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares August 8, 2022
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies August 3, 2022
